-
Marchés
-
Actions
Sustainable finance2025 Euronext ESG Trends ReportLire la suiteA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLire la suiteInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fonds
-
Obligations
European Defence BondsGroupe BPCE lists the first bondLire la suiteFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Produits Structurés
-
Dérivés
Where European Government Bonds Meet the FutureFixed Income derivativesLire la suiteTrade mini bond futures on main European government bonds
-
Marchandises
- Vue d'ensemble
- Vue d'ensemble
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Règlement livraison
- Spécifications et dispositions
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLire la suiteEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLire la suiteJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
CARMAT
Identification
Listing sponsor / Agent
Dexia Securities France
Code ISIN
FR0010907956
Exchange / Market
Euronext Growth
Trading location
Paris
ICB
Medical Equipment
Description de l'activité
Créée le 30 juin 2008, CARMAT SAS est une Jeune Entreprise Biomédicale Innovante financée par TRUFFLE CAPITAL, EADS et le Professeur Carpentier avec le soutien d’OSEO.
L’objectif de Carmat est de proposer un cœur artificiel totalement implantable, incluant les ventricules droit et gauche et dont la conception vise à se rapprocher au maximum du cœur humain. Comptant près de 15 années de développement, ce projet est issu de la collaboration du chirurgien cardio-vasculaire Alain Carpentier et de EADS, dans la mise en œuvre de biomatériaux et de technologies de pointe appliquées au domaine du cœur artificiel.
Site internet
http://www.carmatsas.com
Issuer website
http://www.carmatsas.com
Operation
Date de l'IPO
mer 07/07/2010
Type d'IPO
Initial Public offering
Catégorie
IPO